EP3235812
Tvívetnaðar afleiður af ívakaftór
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
17.5.2012EP published:
4.9.2019EP application number:
17160386.3
EP translation filed:
20.11.2019Grant published:
15.12.2019EPO information:
European Patent Register
Max expiry date:
16.5.2032Expiry date:
16.5.2026Next due date:
31.5.2026
Title:
DEUTERATED DERIVATIVES OF IVACAFTOR
Timeline
Today
17.5.2012EP application
4.9.2019EP Publication
20.11.2019Translation submitted
15.12.2019Registration published
16.5.2026Expires
Owner
Name:
Vertex Pharmaceuticals (Europe) LimitedAddress:
2 Kingdom Street, London W2 6BD, GB
Inventor
Name:
Morgan,, Adam JAddress:
Ashland, MA Massachusetts, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201161487497 PDate:
18.5.2011Country:
US
Classification
Categories:
C07D 215/56, C07B 59/00, A61K 31/47, A61P 11/12
Annual fees
Number
Paid
Expires
Payer
Number: 9
Paid: 30.4.2020
Expires: 16.5.2021
Payer: Sigurjónsson & Thor ehf.
Number: 10
Paid: 3.5.2021
Expires: 16.5.2022
Payer: Sigurjónsson & Thor ehf.
Number: 11
Paid: 3.5.2022
Expires: 16.5.2023
Payer: Patice ehf.
Number: 12
Paid: 23.5.2023
Expires: 16.5.2024
Payer: Árnason Faktor ehf.
Number: 13
Paid: 2.5.2024
Expires: 16.5.2025
Payer: Árnason Faktor ehf.
Number: 14
Paid: 14.5.2025
Expires: 16.5.2026
Payer: Árnason Faktor ehf.